Announcing Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong
Read UMR's Statement on the House Appropriations Committee's Passage of FY23 Labor-HHS Funding Bill
NIH's Role In Sustaining the U.S. Economy | 2022 Update Now Available

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage

Johnson & Johnson Discussions to License its COVID-19 Vaccine to Aspen Reach Advanced Stage

Johnson & Johnson is pleased to reach an advanced stage in its discussions for a potential licensing agreement for its COVID-19 vaccine with Aspen SA Operations (Pty) Ltd, which is based in South Africa. The parties will continue to work toward a definitive agreement that builds on their existing manufacturing collaboration and would enable the … Continued

Johnson & Johnson COVID-19 Vaccine Named One of Time’s Best Inventions of 2021

Yesterday, the editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time’s Best Inventions of 2021.  

“See You Now” Podcast: Vax is Trending

In this episode, we check in with Melody Butler, BSN, RN, CIC, the Founder and Executive Director of Nurses Who Vaccinate, to get an update on how she and nurses around the world are responding, mobilizing, and innovating our vaccination efforts, messaging, and communication strategies. This conversation is particularly relevant at a time when an … Continued

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

Additional data show a booster increases protection 94 percent protection in the U.S. with booster given at two months. Four-fold increase in antibodies when given at two months. 12-fold increase in antibodies when booster given at six months.

Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine

Johnson & Johnson today announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine… The Company is engaging with the U.S. Food and Drug Administration (FDA), U.S. Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA) and other health … Continued

Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company’s COVID-19 Vaccine

We are pleased to confirm the U.S. Food & Drug Administration (FDA) has extended the shelf life for the Johnson & Johnson single-shot COVID-19 vaccine to six months. The decision is based on data from ongoing stability assessment studies, which have demonstrated the vaccine is stable at six months when refrigerated at temperatures of 36 … Continued

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

Johnson & Johnson today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The … Continued

Johnson & Johnson Statement on Supply of its Single-shot COVID-19 Vaccine

Johnson & Johnson confirms the United States Food & Drug Administration (FDA) has authorized two batches of drug substance, manufactured at the Emergent BioSolutions, Inc. Bayview facility, under the Emergency Use Authorization (EUA) for its single-shot COVID-19 vaccine.

J&J Statement on FDA Approval of Shelf Life Extension for Company’s COVID-19 Vaccine

We are pleased to confirm the U.S. Food & Drug Administration (FDA) has authorized an extension of the shelf life for the Johnson & Johnson single-shot COVID-19 vaccine from 3 months to 4.5 months. The decision is based on data from ongoing stability assessment studies, which have demonstrated that the vaccine is stable at 4.5 … Continued

Behind Covid-19 vaccine development

A machine learning model developed jointly by Janssen and MIT data scientists played a key role in the clinical trial process for the Johnson & Johnson Covid-19 vaccine When starting a vaccine program, scientists generally have anecdotal understanding of the disease they’re aiming to target. When Covid-19 surfaced over a year ago, there were so … Continued